Interferon α 2b and ribavirin in severe recurrent cholestatic hepatitis C

Transplantation

Volumn 71, Issue 10, 2001, Pages 1486-1488

  Ong, Janus P ^a   Younossi, Zobair M ^a,b   Gramlich, Terry ^a   Goodman, Zachary ^c   Mayes, James ^a   Sarbah, Steedman ^a   Yen Lieberman, Belinda ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; LIVER ENZYME; RIBAVIRIN;

ADULT; ARTICLE; CASE REPORT; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; DEATH; ENZYME BLOOD LEVEL; FEMALE; GRAFT FAILURE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; JAUNDICE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; VIREMIA;

EID: 0035958118     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200105270-00023     Document Type: Article

References (9)

1. Hepatitis C and liver transplantation
2. Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels
3. Long-term outcome of hepatitis C infection after liver transplantation
4. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation
5. Cholestatic hepatitis C in liver allografts
6. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation
7. Outcome of de novo hepatitis C virus infection in heart transplant recipients
8. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation
9. Hepatitis C: An update on the silent epidemic